Novo Nordisk Pharmaceutical: GLP-1 NDC Listings (Oct 2026)

What FDA’s records state

FDA listing summary for Novo Nordisk Pharmaceutical Industries, LP
Field	What FDA’s record states	Source
Firm, as FDA lists it	Novo Nordisk Pharmaceutical Industries, LP	openFDA NDC
Also listed as	Novo Nordisk	openFDA NDC
FDA labeler code	0169	openFDA NDC
Molecules	Semaglutide, Liraglutide	openFDA NDC
Kinds of listing	Approved product: 23	openFDA NDC
Products and packages	23 products, 33 package NDCs	openFDA NDC
Earliest listing date	Jan 25, 2010	openFDA NDC
Latest listing date	Apr 27, 2026	openFDA NDC
Approved applications cited	BLA208583 (XULTOPHY 100/3.6), held by NOVO, first approved Nov 21, 2016NDA022341 (VICTOZA), held by NOVO NORDISK INC, first approved Jan 25, 2010NDA206321 (SAXENDA), held by NOVO, first approved Dec 23, 2014NDA209637 (OZEMPIC), held by NOVO, first approved Dec 5, 2017NDA213051 (OZEMPIC, RYBELSUS), held by NOVO, first approved Sep 20, 2019NDA215256 (WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD), held by NOVO, first approved Jun 4, 2021NDA218316 (WEGOVY), held by NOVO, first approved Dec 22, 2025	Drugs@FDA

Every GLP-1 product Novo Nordisk Pharmaceutical Industries, LP lists

One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.

GLP-1 products listed with FDA by Novo Nordisk Pharmaceutical Industries, LP
Product	Product NDC	Form and strength	FDA category	Listed	Packages
OzempicSemaglutide	0169-4130	Injection, Solution · Subcutaneous1.34 mg/mL	Approved productNDA · NDA209637	Since Sep 30, 2020Certified through Dec 31, 2027	1 package 0169-4130-13 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 3, 2021
OzempicSemaglutide	0169-4181	Injection, Solution · Subcutaneous0.68 mg/mL	Approved productNDA · NDA209637	Since Oct 7, 2022Certified through Dec 31, 2027	2 packages 0169-4181-13 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Oct 7, 2022 0169-4181-97 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Oct 7, 2022
OzempicSemaglutide	0169-4772	Injection, Solution · Subcutaneous2.68 mg/mL	Approved productNDA · NDA209637	Since Apr 25, 2022Certified through Dec 31, 2027	2 packages 0169-4772-12 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Apr 25, 2022 0169-4772-97 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Apr 25, 2022
OzempicSemaglutide	0169-1704	Tablet · Oral4 mg	Approved productNDA · NDA213051	Since Apr 27, 2026Certified through Dec 31, 2027	1 package 0169-1704-30 30 TABLET in 1 BOTTLE, PLASTIC, since Apr 27, 2026
OzempicSemaglutide	0169-1709	Tablet · Oral9 mg	Approved productNDA · NDA213051	Since Apr 27, 2026Certified through Dec 31, 2027	1 package 0169-1709-30 30 TABLET in 1 BOTTLE, PLASTIC, since Apr 27, 2026
OzempicSemaglutide	0169-1715	Tablet · Oral1.5 mg	Approved productNDA · NDA213051	Since Apr 27, 2026Certified through Dec 31, 2027	2 packages 0169-1715-30 30 TABLET in 1 BOTTLE, PLASTIC, since Apr 27, 2026 0169-1715-90 30 TABLET in 1 BOTTLE, PLASTIC, since Apr 27, 2026
RybelsusSemaglutide	0169-4303	Tablet · Oral3 mg	Approved productNDA · NDA213051	Since Sep 20, 2019Certified through Dec 31, 2027	2 packages 0169-4303-30 30 TABLET in 1 BOTTLE, PLASTIC, since Oct 4, 2021 0169-4303-99 30 TABLET in 1 BOTTLE, PLASTIC, since Oct 4, 2021
RybelsusSemaglutide	0169-4307	Tablet · Oral7 mg	Approved productNDA · NDA213051	Since Sep 20, 2019Certified through Dec 31, 2027	1 package 0169-4307-30 30 TABLET in 1 BOTTLE, PLASTIC, since Oct 4, 2021
RybelsusSemaglutide	0169-4314	Tablet · Oral14 mg	Approved productNDA · NDA213051	Since Sep 20, 2019Certified through Dec 31, 2027	1 package 0169-4314-30 30 TABLET in 1 BOTTLE, PLASTIC, since Oct 4, 2021
WegovySemaglutide	0169-4404	Tablet · Oral4 mg	Approved productNDA · NDA218316	Since Jan 6, 2026Certified through Dec 31, 2027	1 package 0169-4404-31 30 TABLET in 1 BOTTLE, PLASTIC, since Jan 6, 2026
WegovySemaglutide	0169-4409	Tablet · Oral9 mg	Approved productNDA · NDA218316	Since Jan 6, 2026Certified through Dec 31, 2027	1 package 0169-4409-31 30 TABLET in 1 BOTTLE, PLASTIC, since Jan 6, 2026
WegovySemaglutide	0169-4415	Tablet · Oral1.5 mg	Approved productNDA · NDA218316	Since Jan 6, 2026Certified through Dec 31, 2027	2 packages 0169-4415-31 30 TABLET in 1 BOTTLE, PLASTIC, since Jan 6, 2026 0169-4415-92 30 TABLET in 1 BOTTLE, PLASTIC, since Jan 6, 2026
WegovySemaglutide	0169-4425	Tablet · Oral25 mg	Approved productNDA · NDA218316	Since Jan 6, 2026Certified through Dec 31, 2027	1 package 0169-4425-31 30 TABLET in 1 BOTTLE, PLASTIC, since Jan 6, 2026
WegovySemaglutide	0169-4501	Injection, Solution · Subcutaneous1 mg/0.5 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	1 package 0169-4501-14 4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021
WegovySemaglutide	0169-4505	Injection, Solution · Subcutaneous0.5 mg/0.5 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	1 package 0169-4505-14 4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021
WegovySemaglutide	0169-4517	Injection, Solution · Subcutaneous1.7 mg/0.75 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	1 package 0169-4517-14 4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021
WegovySemaglutide	0169-4524	Injection, Solution · Subcutaneous2.4 mg/0.75 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	1 package 0169-4524-14 4 SYRINGE, PLASTIC in 1 CARTON / .75 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021
WegovySemaglutide	0169-4525	Injection, Solution · Subcutaneous0.25 mg/0.5 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	2 packages 0169-4525-14 4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021 0169-4525-94 4 SYRINGE, PLASTIC in 1 CARTON / .5 mL in 1 SYRINGE, PLASTIC, since Jun 5, 2021
WegovySemaglutide	0169-4572	Injection, Solution · Subcutaneous7.2 mg/0.75 mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	1 package 0169-4572-14 4 SYRINGE, PLASTIC in 1 CARTON / .75 mL in 1 SYRINGE, PLASTIC, since Mar 19, 2026
WegovySemaglutide	0169-4915	Injection, Solution · Subcutaneous3.2 mg/mL	Approved productNDA · NDA215256	Since Jun 5, 2021Certified through Dec 31, 2027	None published
SaxendaLiraglutide	0169-2800	Injection, Solution · Subcutaneous6 mg/mL	Approved productNDA · NDA206321	Since Dec 31, 2014Certified through Dec 31, 2027	3 packages 0169-2800-15 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 19, 2015 0169-2800-90 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 19, 2015 0169-2800-97 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 19, 2015
VictozaLiraglutide	0169-4060	Injection · Subcutaneous6 mg/mL	Approved productNDA · NDA022341	Since Jan 25, 2010Certified through Dec 31, 2026	4 packages 0169-4060-12 2 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 25, 2010 0169-4060-13 3 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 25, 2010 0169-4060-90 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Jan 25, 2010 0169-4060-99 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Feb 13, 2015
Xultophy 100/3.6Liraglutide	0169-2911	Injection, Solution · SubcutaneousInsulin Degludec 100 IU/mL; Liraglutide 3.6 mg/mL	Approved productBLA · BLA208583	Since Nov 21, 2016Certified through Dec 31, 2026	1 package 0169-2911-15 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC, since Nov 21, 2016

The rest of its federal record

Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.

503B outsourcing facility register

Not on the register under this name.

GLP-1 warning letters

GLP-1 recalls

Class II, ongoing, reported Jan 7, 2026: Presence of Particulate Matter: Hair was found in a prefilled syringeD-0244-2026 · Novo Nordisk Inc. · matched by NDC
Class II, ongoing, reported Jan 7, 2026: Presence of Particulate Matter: Hair was found in a prefilled syringeD-0245-2026 · Novo Nordisk Inc. · matched by NDC
Class II, ongoing, reported May 7, 2025: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.D-0393-2025 · Cardinal Health Inc. · matched by NDC
Class II, terminated, reported Jun 2, 2021: CGMP Deviations: Intermittent exposure to temperature excursion during storage.D-0536-2021 · Cardinal Health Inc. · matched by NDC
Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0617-2021 · Novo Nordisk Inc · matched by name
Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0618-2021 · Novo Nordisk Inc · matched by NDC
Class II, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0622-2021 · Novo Nordisk Inc · matched by NDC
Class I, terminated, reported Apr 21, 2021: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.D-0623-2021 · Novo Nordisk Inc · matched by NDC

FDA enforcement reports, updated by FDA Sep 23, 2026. Every GLP-1 recall

FDA drug shortage list

To Be Discontinued: Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Novo Nordisk, Inc. · FDA updated Aug 25, 2026
Current: Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Novo Nordisk, Inc. · FDA updated Sep 22, 2026
Current: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Novo Nordisk, Inc. · FDA updated Sep 22, 2026
Current: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Novo Nordisk, Inc. · FDA updated Sep 22, 2026
To Be Discontinued: Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)Novo Nordisk, Inc. · FDA updated Jun 4, 2026
To Be Discontinued: Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)Novo Nordisk, Inc. · FDA updated Jun 4, 2026
To Be Discontinued: Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)Novo Nordisk, Inc. · FDA updated Jun 4, 2026

FDA drug shortages ↗, updated by FDA Oct 2, 2026.

What these listings mean, and what they do not

Approved product. A finished product sold under an approved application (NDA, BLA or ANDA). The approval belongs to the application, which Drugs@FDA lists with its holder; the NDC is only the product's identifier.

A listing is not an approval, and not a quality check. It tells FDA a firm makes, labels or compounds a drug. Whether a product was approved is a question about its application, shown above where there is one. Whether a plant passed inspection is a different record again.

The molecules. Semaglutide is the ingredient in Ozempic, Wegovy, Rybelsus; Liraglutide is the ingredient in Victoza, Saxenda.

“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“A labeler may be a manufacturer, including a repackager or relabeler, or the entity named on the product label.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

Related records

Other firms listing semaglutide and liraglutide

FDA registers on this site

Sources

FDA NDC directory via openFDA ↗, updated by FDA Oct 2, 2026.
Application holders: Drugs@FDA, updated by FDA Oct 2, 2026.
FDA’s National Drug Code Directory page ↗ for the quoted definitions.
Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.